FDA recall record

Tacrolimus Ointment, 0.1%, For Dermatological Use Only, Not for Ophthalmic Use recall — FDA D-1304-2022

Defective Container: Tube split from side seam

Class IIIclassification
D-1304-2022official record ID
Aug 10, 2022report date

Recall record at a glance

Official recordD-1304-2022
CategoryDrug Recalls
ClassificationClass III
FDA record statusOngoing
Recalling firmGlenmark Pharmaceuticals Inc., USA
Report dateAug 10, 2022
Recall initiation dateJul 11, 2022
Quantity654,756 tubes
LocationMahwah, NJ, United States

Official product description

Tacrolimus Ointment, 0.1%, For Dermatological Use Only, Not for Ophthalmic Use, Rx Only, a) 30 g tube, NDC 68462-534-35, b) 60 g tube, NDC 68462-534-65, c) 100 g tube, NDC 68462-534-94, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, Product of India.

Why the product was recalled

Defective Container: Tube split from side seam

Distribution information

Nationwide in the USA

How to read the classification

FDA Class III generally covers situations in which use of or exposure to the product is not likely to cause adverse health consequences. The classification displayed here is taken from the FDA enforcement record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: Letter.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.

Related recall records

Other records from the same recalling company are shown first when available.